10th Tumor Models For Combination Targeted Oncology

Kongressthemen
From Leveraging Emerging Predictive Technologies to Engineering a Human-Physiologically Relevant Models - Deepen Our Understanding of Tumor Biology, Resistance Mechanisms and Dosing Strategy

Following the success of KRAS, HER2, BCMA, drug developers have seen a new wave of the novel, combination targeted oncology surging through pipeline.

Kongressorganizer (PCO)
Monica Mojumder Chan

Anmerkungen
Brochure: https://go.evvnt.com/1067549-3?pid=4832

Speakers: Kimberly Aardalen Scientific Technical Leader Novartis Institutes for Biomedical Research, and more.

https://go.evvnt.com/1067549-2?pid=4832

Frau Monica Mojumder Chan